Oslo, Norway, 28 April 2022

The Annual General Meeting (the "AGM") of Nordic Nanovector ASA (the "Company")
(OSE: NANOV) was held today on 28 April 2022 in Oslo, Norway.

All proposals were resolved by the AGM as presented in the notice convening the
AGM distributed on 6 April 2022. The complete minutes of the AGM are attached to
this release, and are available on www.nordicnanovector.com.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of CD37-targeted therapies
for haematological cancers and immune diseases. Nordic Nanovector's lead
clinical-stage candidate is Betalutin[®], a novel CD37-targeting
radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma
(NHL). NHL is an indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 27 billion by 2029. Nordic
Nanovector retains global marketing rights to Betalutin[®] and intends to
actively participate in the commercialisation of Betalutin[®] in the US and
other major markets. Further information can be found at
www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=ht
t
p%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava.c
o
m%7Cbd8fdb7f05284d3963a108d9d20ae447%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%
7
C637771766496096573%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
L
CJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=xp8WBxqCMdEa4qM%2FjJAyw9bnfalGpQqswXz
S
zRJqqWo%3D&reserved=0).

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.